Shilpa Medicare Makes History: First Indian Company Completes Phase 1 Trial for Recombinant Human Albumin (rHA) 20%

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

SHILPA-Trial

More Like This

PR Newswire associated0

Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance Groundbreaking Pulmonary Therapeutics

PR Newswire associated0

Proliant Health & Biologicals Raises the Albumin Standard with AlbufreeDX: Consistent, Animal-Free Recombinant Human Albumin

PR Newswire associated0

Shilpa Medicare Secures SEC-CDSCO Nod for Nor-Ursodeoxycholic Acid Tablets, Eyes Market Launch for NASH

PR Newswire associated0

MAYPHARM CO., LTD. Launches SKINCOLLA: The World's First Recombinant Human Collagen Filler for Superior Skin Rejuvenation

PR Newswire associated0

SteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin America

Business Wire logo

ReLive Biotechnologies Announces NDA Approval of SpheChon 10-70 spheroids/cm² by the HSA in Singapore, Marking a Milestone in ReLive’s Global Endeavors

PR Newswire associated0

Shilpa Pharma Lifesciences Awarded EcoVadis Gold Medal for Outstanding Sustainability Practices

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy